45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published: assessment threshold met
●Gross / standard charges: assessment threshold met
●Discounted cash price: assessment threshold met
●Payer-specific negotiated rates: assessment threshold met
○Min / max negotiated charges: below assessment threshold
●Free, public, no login required: assessment threshold met
Procedures listed
153,047
Insurances with rates
50
CPT / HCPCS codes
0
Most expensive procedures (gross)
51905029-3127866
$250,094
30237-8900-06 - sipuleucel-T - Susp
Gross
$833,646
51905029-3127866
$175,066
30237-8900-06 - sipuleucel-T - Susp
Gross
$833,646
127538326-3127866
$137,540
00310-4535-30 - tremelimumab actl 20 mg/mL Soln
Gross
$458,465
127538326-3127866
$96,278
00310-4535-30 - tremelimumab actl 20 mg/mL Soln
Gross
$458,465
103958918-3127864
$118,444
69866-1030-05 - autologous cultured chondrocytes 1
Gross
$394,813
103958918-3127864
$82,911
69866-1030-05 - autologous cultured chondrocytes 1
Gross
$394,813
103958919-3127864
$118,444
69866-1030-08 - autologous cultured chondrocytes 1
Gross
$394,813
103958919-3127864
$82,911
69866-1030-08 - autologous cultured chondrocytes 1
Gross
$394,813
101891901-3127866
$113,538
72187-0401-01 - tagraxofusp 1000 mcg/mL Soln
Gross
$378,460
101891901-3127866
$79,477
72187-0401-01 - tagraxofusp 1000 mcg/mL Soln
Gross
$378,460
102534551-3127868
$102,352
71336-1001-01 - givosiran 189 mg/mL Soln
Gross
$341,172
102534551-3127868
$71,646
71336-1001-01 - givosiran 189 mg/mL Soln
Gross
$341,172
105162272-3211899
$100,854
IC-S-PER INS LH VAD ART [MOPB]
Gross
$336,179
105162272-3211899
$70,598
IC-S-PER INS LH VAD ART [MOPB]
Gross
$336,179
101883920-3127866
$92,881
79952-0110-01 - loncastuximab tesirine 10 mg Injec
Gross
$309,604
101883920-3127866
$65,017
79952-0110-01 - loncastuximab tesirine 10 mg Injec
Gross
$309,604
1279402-3127868
$92,072
00003-2328-22 - ipilimumab Soln
Gross
$306,907
1279402-3127868
$64,451
00003-2328-22 - ipilimumab Soln
Gross
$306,907
1287035-3127866
$86,568
76128-0155-75 - porfimer 75. mg REC Injection
Gross
$288,560
1287035-3127866
$60,598
76128-0155-75 - porfimer 75. mg REC Injection
Gross
$288,560
102917747-3127866
$82,180
72493-0103-03 - mitoMYcin 40 mg Kit
Gross
$273,934
102917747-3127866
$57,526
72493-0103-03 - mitoMYcin 40 mg Kit
Gross
$273,934
103469064-3127866
$78,417
00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde
Gross
$261,390
103469064-3127866
$54,892
00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde
Gross
$261,390
104095409-3211899
$78,181
ABIO- SET VNTRC IMPELLA 2.5 9F[MOPB]
Gross
$260,603
104095409-3211899
$54,727
ABIO- SET VNTRC IMPELLA 2.5 9F[MOPB]
Gross
$260,603
104095411-3211899
$78,181
DEV IMPELLA CP 14FRX04.7X75MM - 0048-0003[MOPB]
Gross
$260,603
104095411-3211899
$54,727
DEV IMPELLA CP 14FRX04.7X75MM - 0048-0003[MOPB]
Gross
$260,603
104095673-3211899
$78,181
ABMIABMI- PMP SET IMPELLA RP US 11F EA1/BX10 FIB R
Gross
$260,603
104095673-3211899
$54,727
ABMIABMI- PMP SET IMPELLA RP US 11F EA1/BX10 FIB R
Gross
$260,603
107613797-3211899
$78,181
ABMIABMI- BNDL IMPL W IMPLL PMP C9+ COMP EA1[MOPB]
Gross
$260,603
107613797-3211899
$54,727
ABMIABMI- BNDL IMPL W IMPLL PMP C9+ COMP EA1[MOPB]
Gross
$260,603
1286149-3127868
$75,036
54396-0801-01 - pegloticase Soln
Gross
$250,119
1286149-3127868
$52,525
54396-0801-01 - pegloticase Soln
Gross
$250,119
95367892-3127868
$75,036
60809-0801-01 - pegloticase 8 mg/mL Soln
Gross
$250,119
95367892-3127868
$52,525
60809-0801-01 - pegloticase 8 mg/mL Soln
Gross
$250,119
105162140-3211899
$74,789
IC-INSERT/REPLCE GEN+LDS SGL/DUAL [MOPB]
Gross
$249,296
105162140-3211899
$52,352
IC-INSERT/REPLCE GEN+LDS SGL/DUAL [MOPB]
Gross
$249,296
94990000-3127868
$68,029
57894-0061-03 - ustekinumab 90 mg/mL Soln
Gross
$226,763
94990000-3127868
$47,620
57894-0061-03 - ustekinumab 90 mg/mL Soln
Gross
$226,763
1282361-3127868
$67,023
57665-0002-02 - pegaspargase 3750. Soln
Gross
$223,409
1282361-3127868
$46,916
57665-0002-02 - pegaspargase 3750. Soln
Gross
$223,409
1282362-3127868
$67,023
54482-0301-01 - pegaspargase 3750. Soln
Gross
$223,409
1282362-3127868
$46,916
54482-0301-01 - pegaspargase 3750. Soln
Gross
$223,409
99090561-3127868
$67,023
72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5
Gross
$223,409
99090561-3127868
$46,916
72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5
Gross
$223,409
104788188-3211899
$63,094
BOSTCSRM- DSC- DEFIB CARD TLGN RF HE DR NO KNOWN P
Gross
$210,314
104788188-3211899
$44,166
BOSTCSRM- DSC- DEFIB CARD TLGN RF HE DR NO KNOWN P
Gross
$210,314
104788846-3211899
$63,094
BOSTCSRM- DEFIB CRD TLGN RF HE DR 2CH EA1 SS LCP B
Gross
$210,314
104788846-3211899
$44,166
BOSTCSRM- DEFIB CRD TLGN RF HE DR 2CH EA1 SS LCP B
Gross
$210,314
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 51905029-3127866 | 30237-8900-06 - sipuleucel-T - Susp | $833,646 | $250,094 | — | — | 6 |
| 51905029-3127866 | 30237-8900-06 - sipuleucel-T - Susp | $833,646 | $175,066 | — | — | 10 |
| 127538326-3127866 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $458,465 | $137,540 | — | — | 6 |
| 127538326-3127866 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $458,465 | $96,278 | — | — | 10 |
| 103958918-3127864 | 69866-1030-05 - autologous cultured chondrocytes 1 | $394,813 | $118,444 | — | — | 6 |
| 103958918-3127864 | 69866-1030-05 - autologous cultured chondrocytes 1 | $394,813 | $82,911 | — | — | 10 |
| 103958919-3127864 | 69866-1030-08 - autologous cultured chondrocytes 1 | $394,813 | $118,444 | — | — | 6 |
| 103958919-3127864 | 69866-1030-08 - autologous cultured chondrocytes 1 | $394,813 | $82,911 | — | — | 10 |
| 101891901-3127866 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $378,460 | $113,538 | — | — | 6 |
| 101891901-3127866 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $378,460 | $79,477 | — | — | 10 |
| 102534551-3127868 | 71336-1001-01 - givosiran 189 mg/mL Soln | $341,172 | $102,352 | — | — | 6 |
| 102534551-3127868 | 71336-1001-01 - givosiran 189 mg/mL Soln | $341,172 | $71,646 | — | — | 10 |
| 105162272-3211899 | IC-S-PER INS LH VAD ART [MOPB] | $336,179 | $100,854 | — | — | 6 |
| 105162272-3211899 | IC-S-PER INS LH VAD ART [MOPB] | $336,179 | $70,598 | — | — | 10 |
| 101883920-3127866 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $309,604 | $92,881 | — | — | 6 |
| 101883920-3127866 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $309,604 | $65,017 | — | — | 10 |
| 1279402-3127868 | 00003-2328-22 - ipilimumab Soln | $306,907 | $92,072 | — | — | 6 |
| 1279402-3127868 | 00003-2328-22 - ipilimumab Soln | $306,907 | $64,451 | — | — | 10 |
| 1287035-3127866 | 76128-0155-75 - porfimer 75. mg REC Injection | $288,560 | $86,568 | — | — | 6 |
| 1287035-3127866 | 76128-0155-75 - porfimer 75. mg REC Injection | $288,560 | $60,598 | — | — | 10 |
| 102917747-3127866 | 72493-0103-03 - mitoMYcin 40 mg Kit | $273,934 | $82,180 | — | — | 6 |
| 102917747-3127866 | 72493-0103-03 - mitoMYcin 40 mg Kit | $273,934 | $57,526 | — | — | 10 |
| 103469064-3127866 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $261,390 | $78,417 | — | — | 6 |
| 103469064-3127866 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $261,390 | $54,892 | — | — | 10 |
| 104095409-3211899 | ABIO- SET VNTRC IMPELLA 2.5 9F[MOPB] | $260,603 | $78,181 | — | — | 6 |
| 104095409-3211899 | ABIO- SET VNTRC IMPELLA 2.5 9F[MOPB] | $260,603 | $54,727 | — | — | 8 |
| 104095411-3211899 | DEV IMPELLA CP 14FRX04.7X75MM - 0048-0003[MOPB] | $260,603 | $78,181 | — | — | 6 |
| 104095411-3211899 | DEV IMPELLA CP 14FRX04.7X75MM - 0048-0003[MOPB] | $260,603 | $54,727 | — | — | 8 |
| 104095673-3211899 | ABMIABMI- PMP SET IMPELLA RP US 11F EA1/BX10 FIB R | $260,603 | $78,181 | — | — | 6 |
| 104095673-3211899 | ABMIABMI- PMP SET IMPELLA RP US 11F EA1/BX10 FIB R | $260,603 | $54,727 | — | — | 8 |
| 107613797-3211899 | ABMIABMI- BNDL IMPL W IMPLL PMP C9+ COMP EA1[MOPB] | $260,603 | $78,181 | — | — | 6 |
| 107613797-3211899 | ABMIABMI- BNDL IMPL W IMPLL PMP C9+ COMP EA1[MOPB] | $260,603 | $54,727 | — | — | 8 |
| 1286149-3127868 | 54396-0801-01 - pegloticase Soln | $250,119 | $75,036 | — | — | 6 |
| 1286149-3127868 | 54396-0801-01 - pegloticase Soln | $250,119 | $52,525 | — | — | 10 |
| 95367892-3127868 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $250,119 | $75,036 | — | — | 6 |
| 95367892-3127868 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $250,119 | $52,525 | — | — | 10 |
| 105162140-3211899 | IC-INSERT/REPLCE GEN+LDS SGL/DUAL [MOPB] | $249,296 | $74,789 | — | — | 6 |
| 105162140-3211899 | IC-INSERT/REPLCE GEN+LDS SGL/DUAL [MOPB] | $249,296 | $52,352 | — | — | 10 |
| 94990000-3127868 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $226,763 | $68,029 | — | — | 6 |
| 94990000-3127868 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $226,763 | $47,620 | — | — | 10 |
| 1282361-3127868 | 57665-0002-02 - pegaspargase 3750. Soln | $223,409 | $67,023 | — | — | 6 |
| 1282361-3127868 | 57665-0002-02 - pegaspargase 3750. Soln | $223,409 | $46,916 | — | — | 10 |
| 1282362-3127868 | 54482-0301-01 - pegaspargase 3750. Soln | $223,409 | $67,023 | — | — | 6 |
| 1282362-3127868 | 54482-0301-01 - pegaspargase 3750. Soln | $223,409 | $46,916 | — | — | 10 |
| 99090561-3127868 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $223,409 | $67,023 | — | — | 6 |
| 99090561-3127868 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $223,409 | $46,916 | — | — | 10 |
| 104788188-3211899 | BOSTCSRM- DSC- DEFIB CARD TLGN RF HE DR NO KNOWN P | $210,314 | $63,094 | — | — | 6 |
| 104788188-3211899 | BOSTCSRM- DSC- DEFIB CARD TLGN RF HE DR NO KNOWN P | $210,314 | $44,166 | — | — | 8 |
| 104788846-3211899 | BOSTCSRM- DEFIB CRD TLGN RF HE DR 2CH EA1 SS LCP B | $210,314 | $63,094 | — | — | 6 |
| 104788846-3211899 | BOSTCSRM- DEFIB CRD TLGN RF HE DR 2CH EA1 SS LCP B | $210,314 | $44,166 | — | — | 8 |
Showing top 50 of 153,047 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.